Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752895 · ClinicalTrials.gov registry record · Phase 2
American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 293
- Enrollment target
NCT00752895 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 293 participants.
The verdict
NCT00752895, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 293 participants
- Enrollment target
Study Summary
RATIONALE: American ginseng extract may prevent or reduce acute respiratory illness in patients with chronic lymphocytic leukemia. It is not yet known whether American ginseng extract is more effective than a placebo in preventing respiratory infections. PURPOSE: This randomized trial is studying the side effects of American ginseng extract and to see how well it works compared with a placebo in preventing respiratory infection and in reducing antibiotic use in patients with chronic lymphocytic leukemia.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT American ginseng
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2008-09-01 |
| Est. Completion | 2009-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752895
The ClinicalTrials.gov registry entry for NCT00752895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00752895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00752895 about?
NCT00752895 is a clinical study titled "American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL". RATIONALE: American ginseng extract may prevent or reduce acute respiratory illness in patients with chronic lymphocytic leukemia. It is not yet known whether American ginseng extract is more effective than a placebo in preventing respiratory infections. PURPOSE: This randomized trial is studying t...
What is the current status of trial NCT00752895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2008-09-01. Estimated completion is 2009-06-01.
What interventions are being tested in trial NCT00752895?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), American ginseng (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00752895?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.